Arvinas (NASDAQ:ARVN) Reaches New 1-Year High at $28.50
Arvinas Inc (NASDAQ:ARVN)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $28.50 and last traded at $28.47, with a volume of 10337 shares changing hands. The stock had previously closed at $26.55.
Several equities research analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Arvinas in a report on Monday, August 5th. They issued an “overweight” rating and a $42.00 price target on the stock. Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 price target (up previously from $32.00) on shares of Arvinas in a report on Wednesday. ValuEngine lowered shares of Arvinas from a “hold” rating to a “sell” rating in a report on Friday, November 8th. Roth Capital assumed coverage on shares of Arvinas in a report on Thursday. They issued a “buy” rating and a $35.00 price target on the stock. Finally, BMO Capital Markets assumed coverage on shares of Arvinas in a report on Thursday, September 12th. They issued an “outperform” rating and a $34.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $32.75.
The stock has a market cap of $896.04 million, a P/E ratio of -1.20 and a beta of 2.13. The company has a current ratio of 6.79, a quick ratio of 6.79 and a debt-to-equity ratio of 0.03. The company’s fifty day simple moving average is $20.72 and its 200-day simple moving average is $22.66.
In other news, Director Liam Ratcliffe bought 680,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average price of $22.00 per share, with a total value of $14,960,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ian Taylor sold 10,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $28.00, for a total transaction of $280,000.00. Following the completion of the sale, the insider now directly owns 55,496 shares in the company, valued at approximately $1,553,888. The disclosure for this sale can be found here. 31.77% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of ARVN. BlackRock Inc. grew its holdings in shares of Arvinas by 124.5% in the 2nd quarter. BlackRock Inc. now owns 1,038,838 shares of the company’s stock worth $22,845,000 after purchasing an additional 576,137 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Arvinas by 65.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 688,623 shares of the company’s stock worth $15,143,000 after purchasing an additional 273,623 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Arvinas by 14,782.2% in the 2nd quarter. Bank of America Corp DE now owns 232,609 shares of the company’s stock worth $5,116,000 after purchasing an additional 231,046 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Arvinas in the 2nd quarter worth about $4,834,000. Finally, Vanguard Group Inc. grew its holdings in shares of Arvinas by 33.0% in the 2nd quarter. Vanguard Group Inc. now owns 545,305 shares of the company’s stock worth $11,991,000 after purchasing an additional 135,177 shares during the last quarter. 46.79% of the stock is currently owned by institutional investors and hedge funds.
Arvinas Company Profile (NASDAQ:ARVN)
Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.
Featured Story: Fibonacci Channel
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.